8-K Announcements
6Apr 7, 2026·SEC
Mar 5, 2026·SEC
Feb 26, 2026·SEC
MetLife, Inc. (MET) fundamental analysis — strengths, weaknesses & financial health based on data analysis
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MetLife, Inc. (MET) stock price & volume — 10-year historical chart
MetLife, Inc. (MET) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
MetLife, Inc. (MET) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 4, 2026 | $2.58vs $2.34+10.3% | $23.8Bvs $27.2B-12.5% |
| Q4 2025 | Nov 5, 2025 | $2.34vs $2.31+1.3% | $16.9Bvs $18.6B-9.4% |
| Q3 2025 | Aug 6, 2025 | $2.02vs $2.15-6.0% | $17.3Bvs $18.5B-6.4% |
| Q2 2025 | Apr 30, 2025 | $1.96vs $2.00-2.0% | $18.3Bvs $18.4B-0.5% |
MetLife, Inc. (MET) competitors in Diversified global life and asset managers — business model, growth, and fundamentals comparison
MetLife, Inc. (MET) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MetLife, Inc. (MET) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.53B | 62.31B | 67.94B | 69.62B | 67.89B | 63.37B | 67.97B | 67.71B | 69.94B | 70.76B |
| Revenue Growth % | -1.33% | 2.94% | 9.04% | 2.47% | -2.49% | -6.66% | 7.26% | -0.38% | 3.29% | 0.06% |
| Medical Costs & Claims | 46.57B | 48.85B | 52.04B | 53.43B | 52.42B | 46.53B | 49.03B | 50.42B | 50.94B | 53.7B |
| Medical Cost Ratio % | 76.94% | 78.39% | 76.6% | 76.75% | 77.21% | 73.43% | 72.14% | 74.47% | 72.83% | 75.89% |
| Gross Profit | 13.96B▲ 0% | 13.46B▼ 3.5% | 15.9B▲ 18.1% | 16.19B▲ 1.8% | 15.47B▼ 4.4% | 16.84B▲ 8.8% | 18.94B▲ 12.5% | 17.29B▼ 8.7% | 19B▲ 9.9% | 17.06B▲ 0% |
| Gross Margin % | 23.06% | 21.61% | 23.4% | 23.25% | 22.79% | 26.57% | 27.86% | 25.53% | 27.17% | 24.11% |
| Gross Profit Growth % | -13.69% | -3.53% | 18.11% | 1.82% | -4.45% | 8.83% | 12.48% | -8.7% | 9.89% | - |
| Operating Expenses | 9.67B | 9.93B | 9.59B | 9.39B | 8.54B | 8.32B | 12.57B | 15.13B | 13.38B | 12.14B |
| OpEx / Revenue % | 15.98% | 15.93% | 14.12% | 13.49% | 12.58% | 13.13% | 18.5% | 22.34% | 19.13% | 17.15% |
| Depreciation & Amortization | 652M | 795M | 628M | 630M | 619M | 694M | 673M | 718M | 714M | 0 |
| Combined Ratio % | 92.93% | 94.32% | 90.72% | 90.24% | 89.8% | 86.56% | 90.64% | 96.81% | 91.96% | 93.04% |
| Operating Income | 4.28B▲ 0% | 3.54B▼ 17.4% | 6.31B▲ 78.4% | 6.79B▲ 7.7% | 6.93B▲ 1.9% | 8.52B▲ 23.0% | 6.36B▼ 25.3% | 2.16B▼ 66.0% | 5.62B▲ 160.0% | 4.92B▲ 0% |
| Operating Margin % | 7.07% | 5.68% | 9.28% | 9.76% | 10.2% | 13.44% | 9.36% | 3.19% | 8.04% | 6.96% |
| Operating Income Growth % | -24.24% | -17.4% | 78.37% | 7.74% | 1.94% | 22.97% | -25.29% | -66.03% | 160.04% | - |
| EBITDA | 4.93B | 4.33B | 6.93B | 7.42B | 7.55B | 9.21B | 7.04B | 2.88B | 6.34B | 5.98B |
| EBITDA Margin % | 8.15% | 6.95% | 10.21% | 10.67% | 11.12% | 14.54% | 10.35% | 4.25% | 9.06% | 8.45% |
| Interest Expense | 1.16B | 1.13B | 1.12B | 955M | 913M | 920M | 938M | 1.04B | 1.04B | 1.06B |
| Non-Operating Income | -1.16B | -1.13B | -1.12B | -955M | -913M | -920M | -938M | -1.04B | -1.04B | -1.06B |
| Pretax Income | 4.28B▲ 0% | 3.54B▼ 17.4% | 6.31B▲ 78.4% | 6.79B▲ 7.7% | 6.93B▲ 1.9% | 8.52B▲ 23.0% | 6.36B▼ 25.3% | 2.16B▼ 66.0% | 5.62B▲ 160.0% | 4.92B▲ 0% |
| Pretax Margin % | 7.07% | 5.68% | 9.28% | 9.76% | 10.2% | 13.44% | 9.36% | 3.19% | 8.04% | 6.96% |
| Income Tax | 693M | -1.47B | 1.18B | 886M | 1.51B | 1.64B | 1.06B | 560M | 1.18B | 1.06B |
| Effective Tax Rate % | 16.19% | -41.57% | 18.69% | 13.04% | 21.78% | 19.28% | 16.69% | 25.9% | 20.95% | 21.58% |
| Net Income | 850M▲ 0% | 4.01B▲ 371.8% | 5.12B▲ 27.8% | 5.9B▲ 15.1% | 5.41B▼ 8.3% | 6.86B▲ 26.8% | 5.28B▼ 22.9% | 1.58B▼ 70.1% | 4.43B▲ 180.5% | 3.84B▲ 0% |
| Net Margin % | 1.4% | 6.44% | 7.54% | 8.47% | 7.96% | 10.82% | 7.77% | 2.33% | 6.33% | 5.43% |
| Net Income Growth % | -84.18% | 371.76% | 27.76% | 15.15% | -8.34% | 26.78% | -22.92% | -70.14% | 180.48% | 2.1% |
| EPS (Diluted) | 0.67▲ 0% | 3.74▲ 458.2% | 4.91▲ 31.3% | 6.06▲ 23.4% | 5.68▼ 6.3% | 7.65▲ 34.7% | 6.30▼ 17.6% | 1.81▼ 71.3% | 5.94▲ 228.2% | 5.74▲ 0% |
| EPS Growth % | -85.34% | 458.21% | 31.28% | 23.42% | -6.27% | 34.68% | -17.65% | -71.27% | 228.18% | 7.06% |
| EPS (Basic) | 0.68 | 3.74 | 4.95 | 6.10 | 5.72 | 7.70 | 6.35 | 1.82 | 5.98 | - |
| Diluted Shares Outstanding | 1.1B | 1.04B | 1.01B | 944.4M | 913.2M | 869.4M | 808.9M | 762.43M | 711.1M | 669.1M |
MetLife, Inc. (MET) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 898.76B | 719.89B | 687.54B | 740.46B | 795.15B | 759.71B | 663.07B | 687.58B | 677.46B | 719.73B |
| Asset Growth % | 2.37% | -19.9% | -4.49% | 7.7% | 7.38% | -4.46% | -12.72% | 3.7% | -1.47% | 6.16% |
| Total Investment Assets | 667.65B | 313.8B | 436.21B | 473.8B | 508.52B | 494.82B | 433.29B | 434.34B | 435.38B | 4M |
| Long-Term Investments | 368.67B | 0 | 134.01B | 142.13B | 149.81B | 375.49B | 151.58B | 152.93B | 314.67B | 1.31T |
| Short-Term Investments | 298.98B | 313.8B | 302.2B | 331.67B | 358.71B | 347.45B | 281.71B | 281.41B | 80.5B | 94.54B |
| Total Current Assets | 37.95B | 21.09B | 23.34B | 368.71B | 396.38B | 55.36B | 296.98B | 331.21B | 69.76B | 0 |
| Cash & Equivalents | 12.65B | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 20.07B | 20.23B |
| Receivables | 15.46B | 18.42B | 19.64B | 20.44B | 17.87B | 17.33B | 17.41B | 30.2B | 30.77B | 137.18B |
| Other Current Assets | -289.15B | -323.83B | -16.06B | 0 | 0 | -329.47B | -22.34B | -1.03B | -61.58B | -156.18B |
| Goodwill & Intangibles | 9.22B | 9.59B | 9.42B | 9.31B | 10.11B | 9.54B | 9.3B | 9.24B | 8.9B | 36.17B |
| Goodwill | 9.22B | 9.59B | 9.42B | 9.31B | 10.11B | 9.54B | 9.3B | 9.24B | 8.9B | 9.1B |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PP&E (Net) | 2.4B | 0 | 2.6B | 2.79B | 2.8B | 0 | 3.46B | 3.56B | 1.85B | 1.62B |
| Other Assets | -7.51B | 0 | 513.18B | 569.64B | 612.63B | -385.02B | 476.1B | 154.21B | -325.42B | -351.43B |
| Total Liabilities | 831.06B | 661.02B | 634.58B | 674.08B | 720.33B | 691.96B | 632.95B | 657.33B | 649.75B | 690.53B |
| Total Debt | 21.13B | 19.31B | 16.24B | 16.85B | 18.15B | 17.43B | 17.98B | 18.83B | 18.71B | 19.83B |
| Net Debt | 7.2B | 6.61B | 423M | 253M | -1.65B | -2.62B | -2.21B | -1.81B | -1.35B | -401M |
| Long-Term Debt | 20.88B | 19.95B | 15.98B | 16.62B | 17.76B | 17.09B | 17.75B | 18.68B | 18.24B | 19.45B |
| Short-Term Debt | 242M | 477M | 268M | 235M | 393M | 341M | 175M | 119M | 465M | 378M |
| Total Current Liabilities | 0 | 26.51B | 25.5B | 235M | 393M | 32.28B | 0 | 119M | 0 | 0 |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 2.83B | 0 | 0 | 0 |
| Other Current Liabilities | -938M | 25.04B | 24.12B | -1.04B | -716M | 29.77B | -3.39B | -386M | -850M | -747M |
| Deferred Taxes | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.57B |
| Other Liabilities | 810.18B | 607.79B | 618.6B | 648.37B | 691.57B | 616.78B | 615.14B | 637B | 607.23B | 689.21B |
| Total Equity | 67.7B▲ 0% | 58.87B▼ 13.0% | 52.96B▼ 10.0% | 66.38B▲ 25.3% | 74.82B▲ 12.7% | 67.75B▼ 9.4% | 30.13B▼ 55.5% | 30.25B▲ 0.4% | 27.7B▼ 8.4% | 29.19B▲ 0% |
| Equity Growth % | -1.16% | -13.05% | -10.04% | 25.35% | 12.71% | -9.45% | -55.53% | 0.42% | -8.43% | -16.97% |
| Shareholders Equity | 67.53B | 58.68B | 52.74B | 66.14B | 74.56B | 67.48B | 29.88B | 30.02B | 27.45B | 28.94B |
| Minority Interest | 171M | 194M | 217M | 238M | 259M | 267M | 244M | 238M | 258M | 247M |
| Retained Earnings | 34.68B | 26.53B | 28.93B | 33.08B | 36.49B | 41.2B | 40.33B | 40.15B | 42.63B | 43.89B |
| Common Stock | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M |
| Accumulated OCI | 5.37B | 7.43B | 1.72B | 13.05B | 18.07B | 10.92B | -22.62B | -19.24B | -21.19B | -17.57B |
| Return on Equity (ROE) | 1.25% | 6.34% | 9.16% | 9.89% | 7.66% | 9.62% | 10.8% | 5.23% | 15.27% | 13.16% |
| Return on Assets (ROA) | 0.1% | 0.5% | 0.73% | 0.83% | 0.7% | 0.88% | 0.74% | 0.23% | 0.65% | 0.53% |
| Equity / Assets | 7.53% | 8.18% | 7.7% | 8.96% | 9.41% | 8.92% | 4.54% | 4.4% | 4.09% | 4.06% |
| Debt / Equity | 0.31x | 0.33x | 0.31x | 0.25x | 0.24x | 0.26x | 0.60x | 0.62x | 0.68x | 0.68x |
| Book Value per Share | 61.80 | 56.41 | 52.23 | 70.29 | 81.93 | 77.93 | 37.24 | 39.68 | 38.96 | 43.63 |
| Tangible BV per Share | 53.38 | 47.22 | 42.94 | 60.43 | 70.86 | 66.96 | 25.75 | 27.57 | 26.44 | 30.03 |
MetLife, Inc. (MET) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 14.66B | 12.72B | 9.53B | 13.93B | 11.51B | 12.83B | 11.37B | 14.26B | 15.12B | 15.12B |
| Operating CF Growth % | 9.88% | -13.26% | -25.1% | 46.18% | -17.36% | 11.46% | -11.34% | 25.38% | 6% | 20.95% |
| Operating CF / Revenue % | 24.23% | 20.41% | 14.02% | 20% | 16.95% | 20.24% | 16.73% | 21.06% | 21.61% | 21.36% |
| Net Income | 3.58B | 5B | 5.12B | 5.9B | 5.41B | 6.55B | 5.28B | 1.58B | 4.43B | 3.84B |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.36B | 1.68B | -1.59B | 462M | 1.38B | 3.64B | 4.19B | 10.5B | 8.84B | 10.35B |
| Working Capital Changes | 7.72B | 6.04B | 5.99B | 7.56B | 4.72B | 2.63B | 1.9B | 2.18B | 1.85B | 1.85B |
| Cash from Investing | -5.85B | -16.88B | -5.63B | -17.59B | -18.57B | -11.19B | -2.62B | -10.25B | -11.49B | -16.68B |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 4.36B | 0 | -1.17B | 0 | 0 |
| Acquisitions | 385M | -1.28B | 0 | -1.08B | -1.68B | 3.27B | -709M | -755M | -358M | -3M |
| Purchase of Investments | -154.63B | -115.47B | -108.16B | -91.79B | -93.58B | -109.32B | -104.64B | -84.27B | -82.14B | -69.36B |
| Sale/Maturity of Investments | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 4M |
| Other Investing | -9.03B | -1.65B | -7.61B | -4.73B | -2.36B | -20.29B | -5.7B | -143M | 1.07B | -20.81B |
| Cash from Financing | -3.5B | -906M | -2.8B | 4.57B | 10.73B | -1.38B | -9.95B | -2.94B | -3.13B | 642M |
| Dividends Paid | -1.84B | -1.82B | -1.82B | -1.82B | -1.86B | -1.84B | -1.78B | -1.76B | -1.73B | -1.71B |
| Share Repurchases | -372M | -2.93B | -3.99B | -2.29B | -2.15B | -4.8B | -3.33B | -3.1B | -3.21B | -2.83B |
| Stock Issued | 0 | 0 | 1.27B | 0 | 1.96B | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance (Net) | -1000K | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K | 1000K | -1000K | 0 |
| Other Financing | 61M | 4.21B | 3.64B | 8.27B | 11.9B | 5.9B | -5.72B | 1.05B | 2.79B | 4.86B |
| Net Change in Cash | -101M▲ 0% | 50M▲ 149.5% | 3.12B▲ 6140.0% | 777M▼ 75.1% | 3.2B▲ 311.5% | 252M▼ 92.1% | 148M▼ 41.3% | 444M▲ 200.0% | -571M▼ 228.6% | -1.53B▲ 0% |
| Exchange Rate Effect | -1000K | 1000K | 1000K | -1000K | -1000K | -1000K | 1000K | -1000K | -1000K | 2M |
| Cash at Beginning | 12.75B | 12.65B | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 22.18B |
| Cash at End | 17.88B | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 20.07B | 20.23B |
| Free Cash Flow | 14.66B▲ 0% | 12.72B▼ 13.3% | 9.53B▼ 25.1% | 13.93B▲ 46.2% | 11.51B▼ 17.4% | 12.83B▲ 11.5% | 11.37B▼ 11.3% | 14.26B▲ 25.4% | 15.12B▲ 6.0% | 15.14B▲ 0% |
| FCF Growth % | 9.88% | -13.26% | -25.1% | 46.18% | -17.36% | 11.46% | -11.34% | 25.38% | 6% | -3.58% |
| FCF Margin % | 24.23% | 20.41% | 14.02% | 20% | 16.95% | 20.24% | 16.73% | 21.06% | 21.61% | 21.4% |
| FCF per Share | 13.38 | 12.19 | 9.4 | 14.74 | 12.6 | 14.75 | 14.06 | 18.7 | 21.26 | 21.26 |
MetLife, Inc. (MET) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 92.93% | 94.32% | 90.72% | 90.24% | 89.8% | 86.56% | 90.64% | 96.81% | 91.96% | 93.04% |
| Medical Cost Ratio | 76.94% | 78.39% | 76.6% | 76.75% | 77.21% | 73.43% | 72.14% | 74.47% | 72.83% | 75.89% |
| Return on Equity (ROE) | 1.25% | 6.34% | 9.16% | 9.89% | 7.66% | 9.62% | 10.8% | 5.23% | 15.27% | 13.16% |
| Return on Assets (ROA) | 0.1% | 0.5% | 0.73% | 0.83% | 0.7% | 0.88% | 0.74% | 0.23% | 0.65% | 0.53% |
| Equity / Assets | 7.53% | 8.18% | 7.7% | 8.96% | 9.41% | 8.92% | 4.54% | 4.4% | 4.09% | 4.06% |
| Book Value / Share | 61.8 | 56.41 | 52.23 | 70.29 | 81.93 | 77.93 | 37.24 | 39.68 | 38.96 | 43.63 |
| Debt / Equity | 0.31x | 0.33x | 0.31x | 0.25x | 0.24x | 0.26x | 0.60x | 0.62x | 0.68x | 0.68x |
| Revenue Growth | -1.33% | 2.94% | 9.04% | 2.47% | -2.49% | -6.66% | 7.26% | -0.38% | 3.29% | 0.06% |
MetLife, Inc. (MET) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 7, 2026·SEC
Mar 5, 2026·SEC
Feb 26, 2026·SEC
MetLife, Inc. (MET) stock FAQ — growth, dividends, profitability & financials explained
MetLife, Inc. (MET) grew revenue by 3.3% over the past year. Growth has been modest.
Yes, MetLife, Inc. (MET) is profitable, generating $3.84B in net income for fiscal year 2024 (6.3% net margin).
Yes, MetLife, Inc. (MET) pays a dividend with a yield of 2.69%. This makes it attractive for income-focused investors.
MetLife, Inc. (MET) has a return on equity (ROE) of 15.3%. This is reasonable for most industries.
MetLife, Inc. (MET) has a combined ratio of 92.0%. A ratio below 100% indicates underwriting profitability.
MetLife, Inc. (MET) financial analysis — history, returns, DCA and operating performance tools
Analyst verdict, bull/bear case, risk factors and peer comparison
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates